Kalpana Singh
Early detection of myocardial infarction (MI) is essential, yet traditional biomarkers like Troponin and CK-MB have limited sensitivity in the initial hours after symptom onset. Emerging biomarkers such as miRNA-208, miRNA-499, and Copeptin show promise for earlier diagnosis, particularly within the first 3 hours. Additionally, markers like GDF-15, sST2, suPAR, H-FABP, sLOX-1, and various RNAs (including N1LR, SNHG1, TTTY15, and HULC) offer potential for improved MI detection and prognostic assessment. Integrating these novel biomarkers could enhance early diagnosis and management of MI, ultimately leading to better patient outcomes.